These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35536097)

  • 1. Paraneoplastic cast nephropathy associated with malignant prolactinoma: A case report and literature review.
    Mohamed M; Brown A; Wood K; Wong E
    Clin Nephrol; 2022 Jul; 98(1):49-53. PubMed ID: 35536097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant Prolactinoma With Liver Metastases Masquerading as Metastatic Gastrointestinal Stromal Tumor: A Case Report and Literature Review.
    Hong AR; Yoon JH; Kim HK; Kang HC
    Front Endocrinol (Lausanne); 2020; 11():451. PubMed ID: 32760348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late development of intraventricular papillary pituitary carcinoma after irradiation of prolactinoma.
    Tena-Suck ML; Salinas-Lara C; Sánchez-García A; Rembao-Bojórquez D; Ortiz-Plata A
    Surg Neurol; 2006 Nov; 66(5):527-33; discussion 533. PubMed ID: 17084204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Macroprolactinoma at 6 years of age: diagnostic difficulties].
    Oliveira Mda C; Abech DD; Barbosa-Coutinho LM; Ferreira NP
    Arq Neuropsiquiatr; 1992 Sep; 50(3):397-401. PubMed ID: 1308423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactinomas.
    Glezer A; Bronstein MD
    Endocrinol Metab Clin North Am; 2015 Mar; 44(1):71-8. PubMed ID: 25732643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
    Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant prolactinoma: case report and review of the literature.
    Popadić A; Witzmann A; Buchfelder M; Eiter H; Komminoth P
    Surg Neurol; 1999 Jan; 51(1):47-54; discussion 54-5. PubMed ID: 9952123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new.
    Chanson P; Maiter D
    Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant myasthenia gravis and macroprolactinoma: the immunomodulatory role of prolactin and its potential therapeutic use.
    Harris SM; Leong HM; Chowdhury R; Ellis C; Brennan J; Scobie IN
    Endocrine; 2014 Feb; 45(1):9-14. PubMed ID: 23749585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactinomas.
    Huynh PP; Ishii LE; Ishii M
    JAMA; 2021 Jan; 325(2):195. PubMed ID: 33433577
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
    Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
    Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant prolactinoma: case report and review of the literature.
    Kars M; Roelfsema F; Romijn JA; Pereira AM
    Eur J Endocrinol; 2006 Oct; 155(4):523-34. PubMed ID: 16990651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 22-year-old man with severe osteoporosis due to prolactinoma.
    Dandinoğlu T; Akarsu S; Tekin L; Arbal S; Dinçer U
    J Clin Rheumatol; 2013 Sep; 19(6):341-3. PubMed ID: 23965473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reversible blindness caused by an invasive prolactinoma].
    Schöfl-Siegert B; Brabant G; von zur Mühlen A; Schöfl C
    Dtsch Med Wochenschr; 2001 May; 126(21):621-4. PubMed ID: 11413749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
    Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF
    World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperprolactinemia unrelated to prolactinoma].
    Krysiak R; Okopień B
    Wiad Lek; 2014; 67(2 Pt 1):101-11. PubMed ID: 25764785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prolactinoma].
    Glezer A; Bronstein MD
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary prolactin-secreting tumor formation: recent developments.
    Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
    Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of psychosis associated with a prolactinoma: case report and review of the literature.
    Ali S; Miller KK; Freudenreich O
    Psychosomatics; 2010; 51(5):370-6. PubMed ID: 20833935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.